Biocair (Cambridge, UK) has created a specialist logistics team to meet the complex needs of the rapidly expanding cell and gene therapy (CGT) sector.
The company is continuing to develop a team of over 30 dedicated specialists to deliver 24-hour global support for cell and gene therapy service users, it is reported.
The investment, says Biocair, will position the company “at the forefront of personalized logistics, connecting innovative drug developers with patients.”
Biocair plans to double the size of the team over the next 12 months. The company plans to recruit personnel in key regions, including Europe, the Middle East and Africa (EMEA), Asia-Pacific (APAC) and the US over the next five years. The CGT market was valued at USD4.99 billion in 2021 and is forecast to reach USD 36.92 billion by 2027.
Biocair UK Cell and Gene Therapy Lead, Kinga Lovasz, commented: “This new team of experts will enhance Biocair’s agility in the field and enable us to develop new logistics solutions, such as advanced packaging and tracking technologies, to ensure materials arrive on-time and in-full anywhere across the globe.”
LogiPharma Unpacked: Highlights, Key Insights, and the Road to 2025
October 16th 2024In this special post-show episode, we sit down with Ryan Portela, Head of Production for LogiPharma, to reflect on the highlights and key takeaways from this year’s event. From attendee feedback to the most impactful sessions, Ryan shares insider insights and discusses how the momentum from 2024 will continue to shape the future of pharma supply chains. Plus, get a sneak peek into the exciting plans for LogiPharma's 20th Anniversary in 2025.
Boosting Patient Adherence: The Power of Clinical Support Programs
October 3rd 2024In this podcast, we speak with Amanda Scholz, UBC Senior Clinical Program Manager, MHA, BSN, RN as we discuss the important role that clinical adherence programs play in empowering patients and bolster persistence to prescribed life-changing medications throughout their journey.